Head-to-head evidence
DD01 vs orforglipron
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
DD01
Developed by D&D Pharmatech and partners
NCT06410924 · Phase 2 · completed
This randomized, triple-blind, placebo-controlled Phase 2 trial enrolled 67 people with fatty liver disease and measured the proportion who achieved at least a 30% reduction in liver fat, measured by MRI scan, after 12 weeks. DD01 met this imaging-based endpoint far more often than placebo (75.8% vs 11.8%), though liver-fat reduction on imaging is an earlier marker of benefit rather than the biopsy-confirmed liver-disease improvement that later-stage trials assess.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
orforglipron · Foundayo
Marketed by Eli Lilly
NCT05803421 · Phase 3 · completed
The study is randomized and active-controlled with a large sample of 2,749 participants, but it is open-label rather than blinded. Its primary endpoint is a hard clinical cardiovascular outcome; however, the comparison cannot be judged because no results are currently available.
Next expected readout: February 2027 · NCT06672549 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: DD01's landscape · orforglipron's landscape